<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts | NEJM Resident 360 Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality and morbidity worldwide."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts | NEJM Resident 360"><title>Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.9abb477456c09c550857c30eb1984273.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.2397ba9ed4fcf323e8583aa8bab4eb40.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Cardiology%20-%20Coronary%20Artery%20Disease%20and%20Acute%20Coronary%20Syndrome%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p><a href=#cardiology---coronary-artery-disease-and-acute-coronary-syndrome---fast-facts--nejm-resident-360><h1 id=cardiology---coronary-artery-disease-and-acute-coronary-syndrome---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts | NEJM Resident 360</h1></a><p>Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality and morbidity worldwide. While many patients with CAD are asymptomatic, chest pain is a common presentation. An initial evaluation of chest pain should identify whether the patient is presenting with acute coronary syndrome (ACS), which is an emergency condition characterized by acute myocardial injury (most commonly due to atherosclerotic plaque rupture) or plaque erosion followed by thrombus formation.</p><p>In this section, we will discuss the diagnosis and management of:</p><ul><li><p>Coronary Artery Disease</p></li><li><p>Acute Coronary Syndrome</p></li></ul><a href=#coronary-artery-disease><h2 id=coronary-artery-disease><span class=hanchor arialabel=Anchor># </span>Coronary Artery Disease</h2></a><a href=#evaluation><h3 id=evaluation><span class=hanchor arialabel=Anchor># </span>Evaluation</h3></a><p>All patients who present with chest pain should receive a thorough history and physical examination to determine whether the pain is cardiac-related and whether the patient is stable vs. unstable. However, a review of the full evaluation of chest pain is beyond the scope of this guide.</p><a href=#features-of-chest-pain-angina><h3 id=features-of-chest-pain-angina><span class=hanchor arialabel=Anchor># </span>Features of Chest Pain (Angina)</h3></a><p>Typical cardiac chest pain or angina is characterized by retrosternal chest discomfort that is provoked by physical exertion or emotional stress and relieved promptly (i.e., &lt;5 minutes) with rest or nitroglycerin treatment. Other symptoms associated with myocardial ischemia include dyspnea, nausea, epigastric discomfort, presyncope, and syncope. Women, elderly patients, and patients with diabetes may present with non-classic chest pain features, and more attention needs to be paid to these populations.</p><p><strong>High-risk features:</strong> The following table lists features of chest pain presentation suggestive of acute coronary syndrome (ACS, discussed below) that necessitates more-urgent evaluation and management.</p><p><strong>(Source: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. J Am Coll Cardiol 2012.)</strong></p><p><strong>Probable CAD and low-risk features:</strong> Patients deemed to have probable CAD and low-risk features should undergo evaluation to determine the severity of CAD and the risk for myocardial infarction (MI) and its complications.</p><p><strong>Tests for CAD</strong> can be classified as functional or anatomical. Functional tests use a stressor to illicit myocardial oxygen demand and supply mismatch, leading to reversible ischemia, which can be detected by electrocardiogram (ECG), imaging, or both. Anatomical tests directly examine for the presence and severity of plaque(s).</p><ul><li><p><strong>Functional tests</strong></p><ul><li><p><strong>Stressors</strong> include exercise on a treadmill or stationary bicycle.</p><ul><li>Continuous infusion of dobutamine or injection of coronary vasodilators can be used in patients who cannot exercise</li></ul></li><li><p><strong>Imaging</strong> modalities include echocardiography, nuclear myocardial perfusion imaging, and rarely, cardiac magnetic resonance imaging.</p><ul><li>Imaging is typically required for patients who have baseline ECG findings (e.g., left bundle branch block, ventricular-pacing, or resting ST-segment abnormalities) that interfere with ECG interpretation.</li></ul></li></ul></li><li><p><strong>Anatomical tests</strong></p><ul><li><p><strong>Coronary angiography</strong>, the gold standard test for CAD, is associated with procedural risks (e.g., bleeding, infection, MI, or stroke) and may be necessary to guide management (see below) based on findings from other tests.</p></li><li><p><strong>Coronary computed tomography angiography (CCTA)</strong> is a noninvasive alternative to angiography but typically requires patients to have a slow enough heart rate to accurately acquire images timed to the cardiac cycle.</p></li></ul></li><li><p><strong>Coronary artery calcium (CAC)</strong></p><ul><li>For patients at low-to-intermediate risk for CAD, a targeted CT scan can quantify the amount of CAC present, which can identify individuals at very low risk for adverse outcomes.</li></ul></li></ul><p>Each test is associated with different sensitivity, specificity, and prognostic values that depend on the patient’s overall clinical likelihood of having CAD. Choosing an appropriate test can avoid false-positive or -negative results. In patients with an established diagnosis of CAD, testing can guide management when symptoms or clinical status change.</p><p><strong>Predictors of morbidity and mortality</strong> include:</p><ul><li><p>maximum exercise capacity</p></li><li><p>ECG changes during exercise</p></li><li><p>amount of cardiac dysfunction detected by imaging</p></li><li><p>severity of coronary stenoses</p></li></ul><p>For more information on choosing cardiac testing, please see the2021 ACC/AHA guideline for the evaluation and diagnosis of chest pain and the 2014 ACC/AHA guideline for management of stable ischemic heart disease.</p><a href=#management><h3 id=management><span class=hanchor arialabel=Anchor># </span>Management</h3></a><p>In all patients with CAD, the cornerstones of treatment are lifestyle changes and risk-factor management.</p><p><strong>Medical therapies</strong> include:</p><ul><li><p><strong>lipid lowering</strong> with statins, ezetimibe, and/or PCSK9 inhibitors; goal for treatment will be tailored based on a patient’s risk for adverse cardiac events</p></li><li><p><strong>blood pressure control</strong> with goal of &lt;130/80; drugs with concurrent indications in CAD are preferred such as beta-blockers, ACE inhibitors, and ARB (of note, beta blockers can be stopped 3 years after a MI or ACS in favor of another drug with better efficacy for BP control if there’s no other indications for beta blockers, i.e., EF &lt; 40%)</p></li><li><p><strong>diabetes control</strong> with goal HbA1c &lt;7% in those with a long life expectancy and 7% to 9% in those with comorbidities</p></li><li><p>low-dose aspirin indefinitely, with clopidogrel 75 mg daily as an alternative in patients with aspirin intolerance </p></li><li><p><strong>control of chronic stable angina</strong> with beta blockers, calcium channel blockers, long-acting nitrates, and/or ranolazine</p></li><li><p>annual influenza vaccination</p></li></ul><p><strong>Revascularization:</strong> Based on testing, certain patients may have high-risk features that warrant coronary revascularization, either with coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI). The decision for CABG vs. PCI should be made by an interdisciplinary heart team based on the patient’s preferences, comorbidities, and procedural risks. In general, revascularization should be considered for patients with:</p><ul><li><p>≥50% diameter stenosis in the left main coronary artery</p></li><li><p>≥70% stenoses in three major coronary arteries</p></li><li><p>unacceptable angina despite maximum medical therapy</p></li></ul><p>After PCI for revascularization of stable coronary disease, patients are typically treated with low-dose aspirin and clopidogrel (i.e., dual antiplatelet therapy [DAPT]) for ≥1 month after bare metal stent (BMS) placement and for ≥6 months after drug eluting stent (DES) placement. Aspirin can be omitted for patients prescribed anticoagulation treatment (e.g., warfarin or nonvitamin K oral anticoagulants [NOAC]) for another indication.</p><a href=#acute-coronary-syndrome><h2 id=acute-coronary-syndrome><span class=hanchor arialabel=Anchor># </span>Acute Coronary Syndrome</h2></a><p>The three types of ACS can be differentiated based on ECG findings and biomarkers (primarily troponin) as follows:</p><ul><li><p><strong>STEMI</strong> (ST-segment elevation myocardial infarction): ST elevations on ECG with positive biomarkers</p></li><li><p><strong>NSTEMI</strong> (non–ST-segment elevation myocardial infarction): no ST elevations on ECG but positive biomarkers</p></li><li><p><strong>UA</strong> (unstable angina): progressive symptoms of angina, often at rest or with minimal exertion, without ECG changes or positive biomarkers; an increasingly rare clinical syndrome due to the high sensitivity of troponin assays</p></li></ul><a href=#management-of-acute-stemi><h3 id=management-of-acute-stemi><span class=hanchor arialabel=Anchor># </span>Management of Acute STEMI</h3></a><p><strong>Immediate PCI or “primary” PCI</strong> is the preferred management of acute STEMI (especially in patients who present within 12 hours of symptom onset). The shorter the interval between first medical contact and primary PCI, the better the outcome.</p><ul><li><p>An interval of ≤90 minutes is used as a quality measure for hospitals that perform primary PCI. Patients should be transferred to a PCI-capable hospital if time from first medical contact to PCI can be ≤120 minutes.</p></li><li><p>Otherwise, systemic fibrinolytic therapy (e.g., tenecteplase, reteplase, or alteplase) is recommended with subsequent transfer for coronary angiography.</p></li><li><p>Of note, PCI is also recommended for resuscitated patients after a cardiac arrest if the initial ECG is consistent with a STEMI.</p></li></ul><p><strong>Coronary angiography****and revascularization:</strong></p><ul><li><p>Patients with non-ST elevation-acute coronary syndrome (NSTE-ACS) should also undergo immediate coronary angiography and revascularization**,** including patients with cardiogenic shock, severe heart failure, or structural complications of myocardial infarction (e.g., papillary muscle rupture or ventricular septal defect).</p></li><li><p>Patients with NSTE-ACS not requiring immediate PCI should undergo risk stratification to determine whether catheterization within 24 to 48 hours of admission is appropriate. The GRACE risk model and the TIMI risk score are recommended for this purpose; patients with a TIMI risk score >2 benefit from this so-called “early-invasive” approach.</p></li></ul><p>The following table lists the factors associated with appropriate selection of early invasive strategy or ischemia-guided strategy:</p><p><strong>(Source: 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, Circulation 2014. Reprinted with permission. ©2014, American Heart Association, Inc.)</strong></p><p><strong>Medical management of ACS</strong> include:</p><ul><li><p>aspirin (162 to 325 mg, chewed or crushed, given immediately upon initial recognition of potential ACS)</p></li><li><p>antiplatelet therapy with a loading dose of P2Y<sub>12</sub> receptor blocker (clopidogrel, prasugrel, or ticagrelor); ticagrelor or prasugrel (contraindicated in patients with prior stroke or transient ischemic attack) is preferred over clopidogrel in the ACS setting</p></li><li><p>heparin or bivalirudin for patients undergoing invasive management; low-molecular-weight heparin or fondaparinux for patients not undergoing invasive management</p></li><li><p>beta-blocker (avoid in patients with signs of acute heart failure and/or low cardiac output)</p></li><li><p>nitrates for relief of ischemic symptoms</p></li><li><p>morphine for relief of chest pain in STEMI</p></li><li><p>oxygen for patients who are hypoxemic on presentation</p></li></ul><p><strong>Post-ACS management</strong> includes:</p><ul><li><p>low-dose aspirin: for patients taking oral anticoagulant, DAPT and anticoagulation are typically continued for the first month after ACS before discontinuing aspirin</p></li><li><p>P2Y<sub>12</sub> receptor blocker: ≥12 months at maintenance dose to prevent stent thrombosis and recurrent MI; clopidogrel is preferred for patients on concomitant oral anticoagulant; ultimate duration of DAPT may vary based on bleeding risk and type of stent</p></li><li><p>beta-blocker: reduces frequency of ventricular arrythmia, helps with positive left ventricular (LV) remodeling in those with ejection fraction (EF) ≤40% and improves mortality</p></li><li><p>angiotensin-converting enzyme (ACE) inhibitor: for patients with anterior infarction, LVEF ≤40%, hypertension, diabetes, or stable chronic kidney disease (CKD) unless contraindicated; angiotensin receptor blocker (ARB) for patients who cannot tolerate ACE inhibitors secondary to cough or angioedema</p></li><li><p>aldosterone blockade: for patients receiving maximum tolerated therapeutic doses of ACE inhibitor and beta blocker and have LVEF ≤ 40%, diabetes mellitus, or heart failure without significant CKD or hyperkalemia</p></li><li><p>high-intensity statin</p></li><li><p>nitrites as needed</p></li><li><p>implanted cardioverter–defibrillator (ICD) placement: generally not recommended within 90 days of revascularization or within 40 days of myocardial infarction based on the DINAMIT and IRIS studies</p></li></ul><p>The following table describes recommended routine medical therapies for ACS:</p><p><strong>(Source: 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, Circulation 2012. Reprinted with permission. ©2012, American Heart Association, Inc.)</strong></p><p><a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/cardiology/ data-ctx="Cardiology - Coronary Artery Disease and Acute Coronary Syndrome - Fast Facts  NEJM Resident 360" data-src=/cardiology class=internal-link>cardiology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>